{
    "title": "106_hr1039",
    "content": "SECTION 1. CREDIT FOR CLINICAL TESTING RESEARCH EXPENSES ATTRIBUTABLE TO CERTAIN QUALIFIED ACADEMIC INSTITUTIONS INCLUDING TEACHING HOSPITALS. This section introduces a credit for medical innovation expenses under the Internal Revenue Code of 1986. The medical innovation credit under section 38 is 20% of qualified medical innovation expenses exceeding the medical innovation base period amount. Qualified expenses include payments to academic institutions for clinical testing research activities. The term 'clinical testing research activities' refers to human clinical testing conducted at qualified academic institutions in the development of a product before its approval or licensing. The Public Health Service Act defines a 'product' as any drug, biologic, or medical device. A 'qualified academic institution' includes educational institutions and teaching hospitals affiliated with institutions of higher education. The Public Health Service Act defines a 'product' as any drug, biologic, or medical device. A 'qualified academic institution' includes teaching hospitals affiliated with organizations meeting specific requirements, medical research organizations affiliated with teaching hospitals or organizations meeting certain criteria, and charitable research hospitals. The term 'qualified medical innovation expenses' excludes amounts funded by grants or contracts. The 'medical innovation base period amount' is the average annual expenses incurred by the taxpayer in the three years before 1998. The taxpayer must elect to apply this section for any taxable year, with limitations on foreign testing and rules similar to section 41. Coordination with other research and clinical testing credits is required. The taxpayer must elect to apply the medical innovation expenses credit for any taxable year, with limitations on foreign testing and coordination with other research and clinical testing credits. This credit will be part of the general business credit under section 38(b) of the tax code. The section will not apply to expenses paid or incurred after a specified date. The medical innovation expenses credit under section 41A cannot be carried back before January 1, 1999. Additionally, no deduction is allowed for qualified medical innovation expenses as defined in section 41A(b). The medical innovation expenses credit under section 41A cannot be carried back before January 1, 1999. No deduction is allowed for qualified medical innovation expenses as defined in section 41A(b). The deduction for the unused portion of the credit is determined under section 196(c) of the Code. The medical innovation expenses credit under section 41A cannot be carried back before January 1, 1999. No deduction is allowed for qualified medical innovation expenses as defined in section 41A(b). The deduction for the unused portion of the credit is determined under section 196(c) of the Code. Section 41A(a) determines the credit, excluding section 280C(d)(2). A clerical amendment is made to the table of sections for subpart D of part IV of subchapter A of chapter 1 of the Code. The amendments made by section 41A, regarding the credit for medical innovation expenses, will apply to taxable years starting after December 31, 1998."
}